In this podcast, Professor Martin Dreyling from Germany discusses the role of ibrutinib as standard of care for relapsed or refractory mantle cell lymphoma. He also describes how extended follow-up data for ibrutinib has influenced his treatment decisions.
Perspectives on the use of ibrutinib for relapsed/refractory mantle cell lymphoma: Professor Martin Dreyling
28 Apr 2021
Sponsored by Janssen-Cilag Pty Ltd